To include your compound in the COVID-19 Resource Center, submit it here.

Guidant spreading its stent bets

Guidant Corp.'s decision to license Novartis AG's everolimus anti-proliferative compound for use in drug-eluting stents shouldn't be seen as a vote of no confidence in its Achieve paclitaxol-eluting stents, according to the company. Instead, GDT is betting that different anti-proliferatives will work better in different patients, which would give it

Read the full 509 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE